Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial

Journal:

Nature Communications

Published:

2025-07-01

DOI:

10.1038/s41467-025-60757-7

Affiliations:

4

Authors:

6

Go to article

Institutions	Authors	Share
Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, United States of America (USA)	3.833333	0.64
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)	2.166667	0.36

Interested in Oncology and Carcinogenesis?